LipsoBio

LipsoBio is a biotechnology company focused on overcoming the challenges of oral delivery for large-molecule biologics. The company utilizes a proprietary liposomal platform technology designed to encapsulate and protect therapeutic peptides, proteins, and monoclonal antibodies from the harsh environment of the gastrointestinal tract. By enabling oral administration of drugs that currently require injection, such as insulin and GLP-1 agonists, LipsoBio aims to significantly improve patient adherence and quality of life. The company is currently in the pre-clinical stage, targeting major indications including diabetes, obesity, and inflammatory bowel disease. Its approach combines novel lipid formulations with specific targeting moieties to enhance absorption and bioavailability.